Acuta Capital Partners, LLC Unicycive Therapeutics, Inc. Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 2,303,000 shares of UNCY stock, worth $1.24 Million. This represents 2.59% of its overall portfolio holdings.
Number of Shares
2,303,000
Previous 1,979,199
16.36%
Holding current value
$1.24 Million
Previous $811,000
124.29%
% of portfolio
2.59%
Previous 0.82%
Shares
2 transactions
Others Institutions Holding UNCY
# of Institutions
33Shares Held
51.9MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA9.97MShares$5.38 Million1.54% of portfolio
-
Great Point Partners LLC Greenwich, CT8.56MShares$4.62 Million1.62% of portfolio
-
Octagon Capital Advisors LP New York, NY8.56MShares$4.62 Million0.85% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$2.74 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$2.7 Million0.01% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.13M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...